High-dose chemotherapy for primary breast cancer: Facts versus anecdotes

Journal of Clinical Oncology

Volumn 17, Issue 11 SUPPL., 1999, Pages 25-29

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DRUG MEGADOSE; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL RATE;

EID: 0032750091     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Peters W, Rosner G, Vredenburgh J, et al: A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
2. The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FBC therapy. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 3)
3. Bezwoda WR: Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 3)
4. Peters WP, Davis R, Shpall EJ, et al: Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin, and carmustine and autologous bone marrow support for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): A preliminary report. Proc Am Soc Clin Oncol 9:22, 1990 (abstr 80)
5. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
6. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
7. Wolmark N, Fisher B, Anderson S: The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer: Results of NSABP B-24. Breast Cancer Res Treat 46:26, 1997 (abstr 16)
8. DeCillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: An update. Proc Am Soc Clin Oncol 16:130a, 1997 (abstr A459)
9. Rodenhuis S, Richel DJ, van der Wall E, et al: A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Proc Am Soc Clin Oncol 17:123a, 1998 (abstr 470)
10. Hortobagyi GN, Buzdar AU, Champlin R, et al: Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): A randomized trial. Proc Am Soc Clin Oncol 17:123a, 1998 (abstr 471)
11. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The "Philadelphia" Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 1)
12. Lotz JP, Cure H, Janvier M, et al: High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: Results of the French Protocol PEGASE 04. Proc Am Soc Clin Oncol 18:43a, 1999 (abstr 161)
13. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995